An investigation has concluded that the drug is more effective in reducing chronic lumbar pain and has minimal risks of creating dependence compared to traditional opioids.
A large clinical trial in Nature concluded that a new cannabis -derived experimental drug significantly reduces chronic lumbar pain.
The study, conducted by the German pharmacist Vertanical, involved 800 patients suffering from chronic lumbar pain. Participants were randomly designated for take the cannabis extract Patented by the company in liquid form or in a placebo, explains the.
After 12 weeks, the patients who received cannabis -based treatment reported a Reduction of almost two points In pain intensity on a scale of 11 points, compared to a 1.4 point reduction in the placebo group. Apdar of a small look, the researchers considered this difference statistically significant. The patients also reported Improvements in sleep and physical functionwith benefits that continued for an extension phase of six months.
Unlike many cannabis products that are in the dispensaries, Vertanical’s medicine contains only THC microdes, the psychoactive compound of cannabis. Although enough to achieve therapeutic effects, the levels are much lower than those found in edible or recreational oils, minimizing the risk of intoxication and “moca”. Investigators said no evidence of abuse or dependence was observed. Still, driving is not recommended during the early treatment weeks.
Side effects included dizziness, nausea, fatigue and headaches, leading about 17% of participants to interrupt the study. The investigators observed that this abandonment rate was inferior to the typical values for opioidswhich often cause more serious side effects and are more addictive.
“Cannabis can pain significantly And improve physical function in chronic lumbar pain patients without safety concerns normally associated with opioids, ”said lead author Matthias Karst, a pain expert at Hannover Medicine and Vertanical Consultant.
VERTANICAL has already requested approval from European regulatory entities and is working with US authorities to develop a study that can support Food and Drug Administration (FDA) approval.
